FoundationOne™ Heme Enables Identification of Genomic Alterations Not …

FoundationOne™ Heme Enables Identification of Genomic Alterations Not …

Filed under: drug treatment programs maryland

“FoundationOne Heme enables the identification of genomic alterations that are molecular drivers of each patient's cancer which may help to expand and inform treatment options for individual patients, advance the development of new therapies against …
Read more on The Herald | HeraldOnline.com (press release)

Alkermes Presents Data on Two Late-Stage Clinical Candidates, Aripiprazole …

Filed under: drug treatment programs maryland

In October 2013, the U.S. Food and Drug Administration (FDA) granted Fast Track status for ALKS 5461 for the adjunctive treatment of MDD in patients with an inadequate response to standard therapies, and Alkermes plans to begin the phase 3 program in …
Read more on Business Wire (press release)

Alexion Pharmaceuticals, Inc. : New Data Presented at ASH Annual Meeting …

Filed under: drug treatment programs maryland

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that researchers presented data from clinical trials demonstrating the clinical benefits of chronic Soliris® (eculizumab) treatment in patients with atypical hemolytic uremic syndrome (aHUS …
Read more on 4-traders (press release)

Lenalidomide Plus Dex Trumps Standard Tx in Multiple Myeloma

Filed under: drug treatment programs maryland

NEW ORLEANS ? The combination of lenalidomide (Revlimid, Celgene Corporation) plus low-dose dexamethasone (LD) used first-line in the treatment of multiple myeloma significantly improved progression-free and overall survival when compared with …
Read more on Medscape